Open AccessImpact of universal antiretroviral therapy for pregnant and postpartum women on antiretroviral therapy uptake and retention
Author(s) -
Elaine J. Abrams,
tokozo Langwenya,
Averie B. Gachuhi,
Allison Zerbe,
Harriet NuwagabaBiribonwoha,
Simangele Mthethwa-Hleta,
Ruben Sahabo,
Maia Lesosky,
Velephi Okello,
Landon Myer
Publication year - 2019
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002027
Subject(s) - antiretroviral therapy , medicine , pregnancy , human immunodeficiency virus (hiv) , obstetrics , sida , viral disease , viral load , virology , biology , genetics
Universal eligibility for lifelong antiretroviral therapy (ART) for pregnant and breastfeeding women ('Option B+') has been widely adopted, but concerns remain. We tested the hypothesis that the change from CD4+-guided ART eligibility ('Option A'), to Option B+, would improve maternal ART uptake and retention.